Volume 74, Issue 2 pp. 113-118
Full Access

Clinical methods in psychiatric genetics: I. Robustness of genetic marker investigative strategies

E. S. Gershon

Corresponding Author

E. S. Gershon

Clinical Neurogenetics Branch, National Institute of Mental Health, Bethesda, U.S.A.

M.D. Clinical Neurogenetics Branch National Institute of Mental Health Building 10, Room 3N218 9000 Rockville Pike Bethesda, Maryland 20892 U.S.A.Search for more papers by this author
L. R. Goldin

L. R. Goldin

Clinical Neurogenetics Branch, National Institute of Mental Health, Bethesda, U.S.A.

Search for more papers by this author
First published: August 1986
Citations: 89

Abstract

Abstract— Population stratification, secondary effects of illness or treatment, biological heterogeneity of a clinical syndrome, or complex biology underlying a syndrome (where only one component is measured) are conditions which may obscure the association of a genetic risk factor with a clinical syndrome. We consider several investigative strategies under each of these conditions. Only segregation-based paradigms are robust to genetic heterogeneity and population stratification. But secondary effects on the risk factor produced by illness or treatment require other strategies for their detection.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.